Related Experiment Video
Updated: Mar 24, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
When to Start Immunomodulators in Inflammatory Bowel Disease?
1Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Immunomodulators like thiopurines and methotrexate offer benefits for inflammatory bowel disease (IBD) maintenance and steroid-sparing effects. Their use alongside anti-TNF agents is promising but requires further research for optimal patient selection and long-term strategies.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Immunomodulators (IMMs), including thiopurines (TPs) and methotrexate (MTX), are frequently employed in managing inflammatory bowel disease (IBD).
- These agents play a role in both ulcerative colitis (UC) and Crohn's disease (CD).
Purpose of the Study:
- To review the efficacy and safety of TPs and MTX in IBD treatment.
- To evaluate the role of IMMs in combination therapy with anti-TNF agents.
Main Methods:
- Systematic review of existing literature on TPs and MTX in IBD.
- Analysis of clinical trial data and observational studies.
Main Results:
- TPs demonstrate steroid-sparing effects and maintenance efficacy in UC and CD.
- MTX shows limited benefit in UC but modest steroid-sparing and maintenance effects in CD responders.
- Combination of TPs or MTX with infliximab can reduce immunogenicity and improve drug levels, with TPs showing improved outcomes in early CD.
Conclusions:
- IMMs are valuable for non-severe IBD, steroid-dependent disease, and remission maintenance.
- Combination therapy with anti-TNF agents is a developing strategy within treat-to-target approaches, necessitating further investigation into patient selection and long-term management.
- Potential risks of TPs, such as opportunistic infections and malignancies, require careful consideration.
More Related Videos
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...